Identification and Validation of Novel Cerebrospinal Fluid Biomarkers for Staging Early Alzheimer's Disease

BACKGROUND: Ideally, disease modifying therapies for Alzheimer disease (AD) will be applied during the ‘preclinical’ stage (pathology present with cognition intact) before severe neuronal damage occurs, or upon recognizing very mild cognitive impairment. Developing and judiciously administering such...

Descripción completa

Detalles Bibliográficos
Autores principales: Perrin, Richard J., Craig-Schapiro, Rebecca, Malone, James P., Shah, Aarti R., Gilmore, Petra, Davis, Alan E., Roe, Catherine M., Peskind, Elaine R., Li, Ge, Galasko, Douglas R., Clark, Christopher M., Quinn, Joseph F., Kaye, Jeffrey A., Morris, John C., Holtzman, David M., Townsend, R. Reid, Fagan, Anne M.
Formato: Texto
Lenguaje:English
Publicado: Public Library of Science 2011
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3020224/
https://www.ncbi.nlm.nih.gov/pubmed/21264269
http://dx.doi.org/10.1371/journal.pone.0016032

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3020224/
https://www.ncbi.nlm.nih.gov/pubmed/21264269
http://dx.doi.org/10.1371/journal.pone.0016032

Ejemplares similares